{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:27:23Z","timestamp":1793388443327,"version":"4.5.0"},"reference-count":263,"publisher":"Portland Press Ltd.","issue":"6","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Complement is an important component of innate immune defence against pathogens and crucial for efficient immune complex disposal. These core protective activities are dependent in large part on properly regulated complement-mediated inflammation. Dysregulated complement activation, often driven by persistence of activating triggers, is a cause of pathological inflammation in numerous diseases, including neurological diseases. Increasingly, this has become apparent not only in well-recognized neuroinflammatory diseases like multiple sclerosis but also in neurodegenerative and neuropsychiatric diseases where inflammation was previously either ignored or dismissed as a secondary event. There is now a large and rapidly growing body of evidence implicating complement in neurological diseases that cannot be comprehensively addressed in a brief review. Here, we will focus on neurodegenerative diseases, including not only the \u2018classical\u2019 neurodegenerative diseases such as Alzheimer\u2019s disease and Parkinson\u2019s disease, but also two other neurological diseases where neurodegeneration is a neglected feature and complement is implicated, namely, schizophrenia, a neurodevelopmental disorder with many mechanistic features of neurodegeneration, and multiple sclerosis, a demyelinating disorder where neurodegeneration is a major cause of progressive decline. We will discuss the evidence implicating complement as a driver of pathology in these diverse diseases and address briefly the potential and pitfalls of anti-complement drug therapy for neurodegenerative diseases.<\/jats:p>","DOI":"10.1042\/cs20230513","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T03:32:01Z","timestamp":1710905521000},"page":"387-412","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["The complement system in neurodegenerative diseases"],"prefix":"10.1042","volume":"138","author":[{"given":"Jacqui","family":"Nimmo","sequence":"first","affiliation":[{"name":"UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF24 4HQ, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert\u00a0A.J.","family":"Byrne","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF24 4HQ, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoleta","family":"Daskoulidou","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF24 4HQ, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis\u00a0M.","family":"Watkins","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF24 4HQ, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah\u00a0M.","family":"Carpanini","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF24 4HQ, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioleta\u00a0M.","family":"Zelek","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF24 4HQ, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4075-7676","authenticated-orcid":false,"given":"B.\u00a0Paul","family":"Morgan","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF24 4HQ, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"2024041813305235900_B1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1172\/JCI102069","article-title":"Complement and its components in human cerebrospinal fluid","volume":"28","author":"Heidelberger","year":"1949","journal-title":"J. Clin. Invest."},{"key":"2024041813305235900_B2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/BF00687336","article-title":"Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques","volume":"63","author":"Ishii","year":"1984","journal-title":"Acta Neuropathol."},{"key":"2024041813305235900_B3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00685397","article-title":"Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study","volume":"57","author":"Eikelenboom","year":"1982","journal-title":"Acta Neuropathol."},{"key":"2024041813305235900_B4","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1111\/febs.15772","article-title":"Complement cascade functions during brain development and neurodegeneration","volume":"289","author":"Fatoba","year":"2022","journal-title":"FEBS J."},{"key":"2024041813305235900_B5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3389\/fncel.2018.00401","article-title":"Astrocyte heterogeneity in the adult central nervous system","volume":"12","author":"Miller","year":"2018","journal-title":"Front Cell Neurosci."},{"key":"2024041813305235900_B6","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.4049\/jimmunol.155.10.4882","article-title":"Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes","volume":"155","author":"Gasque","year":"1995","journal-title":"J. Immunol."},{"key":"2024041813305235900_B7","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.4049\/jimmunol.154.9.4726","article-title":"Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines","volume":"154","author":"Gasque","year":"1995","journal-title":"J. Immunol."},{"key":"2024041813305235900_B8","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1046\/j.1471-4159.1998.71062487.x","article-title":"Expression of a functional anaphylatoxin C3a receptor by astrocytes","volume":"71","author":"Ischenko","year":"1998","journal-title":"J. Neurochem."},{"key":"2024041813305235900_B9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0002-9440(10)64604-4","article-title":"Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis","volume":"157","author":"Singhrao","year":"2000","journal-title":"Am. J. Pathol."},{"key":"2024041813305235900_B10","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3390\/cells10071812","article-title":"The complement system: a powerful modulator and effector of astrocyte function in the healthy and diseased central nervous system","volume":"10","author":"Pekna","year":"2021","journal-title":"Cells"},{"key":"2024041813305235900_B11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12974-017-0814-9","article-title":"Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain","volume":"14","author":"Fonseca","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"2024041813305235900_B12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/jnr.490400407","article-title":"Complement and cytokine gene expression in cultured microglial derived from postmortem human brains","volume":"40","author":"Walker","year":"1995","journal-title":"J. Neurosci. Res."},{"key":"2024041813305235900_B13","doi-asserted-by":"publisher","first-page":"278e9","DOI":"10.1016\/j.neuron.2017.03.042","article-title":"iPSC-derived human microglia-like cells to study neurological diseases","volume":"94","author":"Abud","year":"2017","journal-title":"Neuron"},{"key":"2024041813305235900_B14","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/glia.24355","article-title":"Complement receptor 1 is expressed on brain cells and in the human brain","volume":"71","author":"Daskoulidou","year":"2023","journal-title":"Glia"},{"key":"2024041813305235900_B15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/7854_2022_383","article-title":"Herpesvirus infections in the human brain: a neural cell model of the complement system derived from induced pluripotent stem cells","volume":"61","author":"Marques","year":"2023","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"2024041813305235900_B16","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/00001756-199604100-00009","article-title":"CD59 expression and complement susceptibility of human neuronal cell line (NTera2)","volume":"7","author":"Agoropoulou","year":"1996","journal-title":"Neuroreport"},{"key":"2024041813305235900_B17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/intimm\/12.7.1015","article-title":"Expression of a complete and functional complement system by human neuronal cells in vitro","volume":"12","author":"Thomas","year":"2000","journal-title":"Int. Immunol."},{"key":"2024041813305235900_B18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0006-8993(98)00346-1","article-title":"Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide","volume":"796","author":"Shen","year":"1998","journal-title":"Brain Res."},{"key":"2024041813305235900_B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023356","article-title":"RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders","volume":"6","author":"Lin","year":"2011","journal-title":"PLoS ONE"},{"key":"2024041813305235900_B20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/glia.10234","article-title":"Expression of complement messenger RNAs and proteins by human oligodendroglial cells","volume":"42","author":"Hosokawa","year":"2003","journal-title":"Glia"},{"key":"2024041813305235900_B21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1046\/j.1365-2567.1996.d01-756.x","article-title":"Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes","volume":"89","author":"Gasque","year":"1996","journal-title":"Immunology"},{"key":"2024041813305235900_B22","article-title":"Science AIfB: Seattle Alzheimer's Disease Brain Cell Atlas","year":"2023"},{"key":"2024041813305235900_B23","article-title":"Science AIfB: Accelerating progress toward understanding the brain","year":"2023"},{"key":"2024041813305235900_B24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"2024041813305235900_B25","doi-asserted-by":"publisher","first-page":"109646","DOI":"10.1016\/j.neuropharm.2023.109646","article-title":"Complement C1q drives microglia-dependent synaptic loss and cognitive impairments in a mouse model of lipopolysaccharide-induced neuroinflammation","volume":"237","author":"Wu","year":"2023","journal-title":"Neuropharmacology"},{"key":"2024041813305235900_B26","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.1007\/s12035-023-03393-w","article-title":"Complement C3 Enhances LPS-Elicited Neuroinflammation and Neurodegeneration Via the Mac1\/NOX2 Pathway","volume":"60","author":"Zhou","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"2024041813305235900_B27","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.molimm.2011.04.003","article-title":"Complement in the brain","volume":"48","author":"Veerhuis","year":"2011","journal-title":"Mol. Immunol."},{"key":"2024041813305235900_B28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12974-020-02024-8","article-title":"The good, the bad, and the opportunities of the complement system in neurodegenerative disease","volume":"17","author":"Schartz","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"2024041813305235900_B29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.molimm.2017.05.025","article-title":"C1q: A fresh look upon an old molecule","volume":"89","author":"Thielens","year":"2017","journal-title":"Mol. Immunol."},{"key":"2024041813305235900_B30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/cmi.2008.2","article-title":"The classical and regulatory functions of C1q in immunity and autoimmunity","volume":"5","author":"Lu","year":"2008","journal-title":"Cell. Mol. Immunol."},{"key":"2024041813305235900_B31","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","article-title":"The classical complement cascade mediates CNS synapse elimination","volume":"131","author":"Stevens","year":"2007","journal-title":"Cell"},{"key":"2024041813305235900_B32","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1126\/science.aaz2288","article-title":"Microglia mediate forgetting via complement-dependent synaptic elimination","volume":"367","author":"Wang","year":"2020","journal-title":"Science (New York, NY)"},{"key":"2024041813305235900_B33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev-immunol-101921-035639","article-title":"Complement in the brain: contributions to neuroprotection, neuronal plasticity, and neuroinflammation","volume":"41","author":"Bohlson","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"2024041813305235900_B34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.molimm.2018.06.267","article-title":"Blood-brain barrier (BBB) and the complement landscape","volume":"102","author":"Alexander","year":"2018","journal-title":"Mol. Immunol."},{"key":"2024041813305235900_B35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.neuron.2012.03.026","article-title":"Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner","volume":"74","author":"Schafer","year":"2012","journal-title":"Neuron"},{"key":"2024041813305235900_B36","doi-asserted-by":"publisher","first-page":"7975","DOI":"10.1073\/pnas.0913449107","article-title":"Enhanced synaptic connectivity and epilepsy in C1q knockout mice","volume":"107","author":"Chu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2024041813305235900_B37","doi-asserted-by":"publisher","first-page":"13029","DOI":"10.1523\/JNEUROSCI.1698-15.2015","article-title":"Complement C3-deficient mice fail to display age-related hippocampal decline","volume":"35","author":"Shi","year":"2015","journal-title":"J. Neurosci."},{"key":"2024041813305235900_B38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"key":"2024041813305235900_B39","volume-title":"World Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support","author":"Gauthier","year":"2022"},{"key":"2024041813305235900_B40","doi-asserted-by":"publisher","first-page":"937486","DOI":"10.3389\/fnagi.2022.937486","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990-2019","volume":"14","author":"Li","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"2024041813305235900_B41","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"2024041813305235900_B42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00281-017-0662-9","article-title":"Complement in the pathogenesis of Alzheimer\u2019's disease","volume":"40","author":"Morgan","year":"2018","journal-title":"Seminars Immunopathol."},{"key":"2024041813305235900_B43","doi-asserted-by":"publisher","first-page":"e13950","DOI":"10.1371\/journal.pone.0013950","article-title":"Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer\u2019s disease","volume":"5","author":"Jones","year":"2010","journal-title":"PLoS ONE"},{"key":"2024041813305235900_B44","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat. Genet."},{"key":"2024041813305235900_B45","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3390\/genes12121990","article-title":"Genetic insights into the impact of complement in Alzheimer's disease","volume":"12","author":"Torvell","year":"2021","journal-title":"Genes"},{"key":"2024041813305235900_B46","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.1073\/pnas.89.21.10016","article-title":"Complement activation by beta-amyloid in Alzheimer disease","volume":"89","author":"Rogers","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2024041813305235900_B47","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/BF00192116","article-title":"Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3","volume":"426","author":"Veerhuis","year":"1995","journal-title":"Virchows Archiv: Int. J. Pathol."},{"key":"2024041813305235900_B48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0197-4580(97)00042-0","article-title":"Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease","volume":"18","author":"Webster","year":"1997","journal-title":"Neurobiol. Aging"},{"key":"2024041813305235900_B49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1742-2094-10-25","article-title":"Complement activation fragment C5a receptors, CD88 and C5L2, are associated with neurofibrillary pathology","volume":"10","author":"Fonseca","year":"2013","journal-title":"J Neuroinflammation"},{"key":"2024041813305235900_B50","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","article-title":"New insights into the genetic etiology of Alzheimer's disease and related dementias","volume":"54","author":"Bellenguez","year":"2022","journal-title":"Nat. Genet."},{"key":"2024041813305235900_B51","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease","volume":"41","author":"Lambert","year":"2009","journal-title":"Nat. Genet."},{"key":"2024041813305235900_B52","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/genes12030443","article-title":"The impact of complement genes on the risk of late-onset Alzheimer's disease","volume":"12","author":"Carpanini","year":"2021","journal-title":"Genes"},{"key":"2024041813305235900_B53","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/ng.440","article-title":"Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease","volume":"41","author":"Harold","year":"2009","journal-title":"Nat. Genet."},{"key":"2024041813305235900_B54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1742-2094-9-179","article-title":"Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study","volume":"9","author":"Cribbs","year":"2012","journal-title":"J Neuroinflammation"},{"key":"2024041813305235900_B55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2024041813305235900_B56","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/ng.801","article-title":"Common variants at MS4A4\/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease","volume":"43","author":"Naj","year":"2011","journal-title":"Nat. Genet."},{"key":"2024041813305235900_B57","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ajmg.b.30668","article-title":"Association of complement factor H Y402H gene polymorphism with Alzheimer's disease","volume":"147B","author":"Zetterberg","year":"2008","journal-title":"Am. J. Med. Genetics Part B, Neuropsychiatric Genetics: Off. Publ. Int. Soc. Psychiatric Genet."},{"key":"2024041813305235900_B58","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3233\/JAD-160420","article-title":"Complement biomarkers as predictors of disease progression in Alzheimer's disease","volume":"54","author":"Hakobyan","year":"2016","journal-title":"J. Alzheimer's Dis.: JAD"},{"key":"2024041813305235900_B59","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40478-016-0277-8","article-title":"CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease","volume":"4","author":"Hu","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"2024041813305235900_B60","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jalz.2019.03.007","article-title":"Inflammatory biomarkers in Alzheimer's disease plasma","volume":"15","author":"Morgan","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2024041813305235900_B61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3233\/JAD-160889","article-title":"The correlation between inflammatory biomarkers and polygenic risk score in Alzheimer's disease","volume":"56","author":"Morgan","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"2024041813305235900_B62","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.jalz.2018.07.223","article-title":"An updated Alzheimer hypothesis: Complement C3 and risk of Alzheimer's disease-A cohort study of 95,442 individuals","volume":"14","author":"Rasmussen","year":"2018","journal-title":"Alzheimers Dement."},{"key":"2024041813305235900_B63","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.1038\/s41380-019-0536-8","article-title":"The complement cascade in Alzheimer's disease: a systematic review and meta-analysis","volume":"26","author":"Krance","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"2024041813305235900_B64","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00702-012-0797-8","article-title":"Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease","volume":"119","author":"Daborg","year":"2012","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"2024041813305235900_B65","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ajpath.2011.01.006","article-title":"Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy","volume":"178","author":"Wang","year":"2011","journal-title":"Am. J. Pathol."},{"key":"2024041813305235900_B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2020.101904","article-title":"Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE \u03b54, sex and age","volume":"198","author":"Ayton","year":"2021","journal-title":"Prog. Neurobiol."},{"key":"2024041813305235900_B67","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/alzrt266","article-title":"Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment","volume":"6","author":"Toledo","year":"2014","journal-title":"Alzheimer's Res. Therapy"},{"key":"2024041813305235900_B68","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00702-002-0763-y","article-title":"CSF markers related to pathogenetic mechanisms in Alzheimer's disease","volume":"109","author":"Mulder","year":"2002","journal-title":"J. Neural Transmission (Vienna, Austria: 1996)"},{"key":"2024041813305235900_B69","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/alz.12799","article-title":"Complement dysregulation and Alzheimer's disease in Down syndrome","volume":"19","author":"Veteleanu","year":"2023","journal-title":"Alzheimers Dement"},{"key":"2024041813305235900_B70","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12974-023-02850-6","article-title":"Alzheimer's disease-associated complement gene variants influence plasma complement protein levels","volume":"20","author":"Veteleanu","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"2024041813305235900_B71","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","article-title":"Complement and microglia mediate early synapse loss in Alzheimer mouse models","volume":"352","author":"Hong","year":"2016","journal-title":"Science (New York, NY)"},{"key":"2024041813305235900_B72","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1083\/jcb.201709069","article-title":"Microglia in Alzheimer's disease","volume":"217","author":"Hansen","year":"2018","journal-title":"J. Cell Biol."},{"key":"2024041813305235900_B73","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s43587-022-00281-1","article-title":"Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer's disease mouse models","volume":"2","author":"Dejanovic","year":"2022","journal-title":"Nat Aging"},{"key":"2024041813305235900_B74","doi-asserted-by":"publisher","first-page":"1322.e7","DOI":"10.1016\/j.neuron.2018.10.014","article-title":"Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies","volume":"100","author":"Dejanovic","year":"2018","journal-title":"Neuron"},{"issue":"392","key":"2024041813305235900_B75","doi-asserted-by":"publisher","first-page":"eaaf6295","DOI":"10.1126\/scitranslmed.aaf6295","article-title":"Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP\/PS1 mice","volume":"9","author":"Shi","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"2024041813305235900_B76","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1523\/JNEUROSCI.0829-08.2008","article-title":"Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia\/macrophage phenotype in amyloid precursor protein transgenic mice","volume":"28","author":"Maier","year":"2008","journal-title":"J. Neurosci."},{"key":"2024041813305235900_B77","doi-asserted-by":"publisher","first-page":"10837","DOI":"10.1073\/pnas.162350199","article-title":"Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice","volume":"99","author":"Wyss-Coray","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2024041813305235900_B78","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40478-022-01404-w","article-title":"Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models","volume":"10","author":"Carpanini","year":"2022","journal-title":"Acta Neuropathologica Commun."},{"key":"2024041813305235900_B79","doi-asserted-by":"publisher","first-page":"e12306","DOI":"10.1002\/jev2.12306","article-title":"Helicobacter pylori-derived outer membrane vesicles contribute to Alzheimer's disease pathogenesis via C3-C3aR signalling","volume":"12","author":"Xie","year":"2023","journal-title":"J. Extracellular Vesicles"},{"key":"2024041813305235900_B80","doi-asserted-by":"publisher","first-page":"1337.e5","DOI":"10.1016\/j.neuron.2018.10.031","article-title":"Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease","volume":"100","author":"Litvinchuk","year":"2018","journal-title":"Neuron"},{"key":"2024041813305235900_B81","doi-asserted-by":"publisher","first-page":"e167501","DOI":"10.1172\/JCI167501","article-title":"Complement C3aR depletion reverses HIF-1\u03b1-induced metabolic impairment and enhances microglial response to A\u03b2 pathology","volume":"133","author":"Gedam","year":"2023","journal-title":"J. Clin. Invest."},{"key":"2024041813305235900_B82","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13024-017-0210-z","article-title":"Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss","volume":"12","author":"Hernandez","year":"2017","journal-title":"Mol. Neurodegener"},{"key":"2024041813305235900_B83","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12974-022-02539-2","article-title":"Modulation of C5a-C5aR1 signaling alters the dynamics of AD progression","volume":"19","author":"Carvalho","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"2024041813305235900_B84","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40478-022-01416-6","article-title":"C5aR1 antagonism alters microglial polarization and mitigates disease progression in a mouse model of Alzheimer's disease","volume":"10","author":"Gomez-Arboledas","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"2024041813305235900_B85","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3233\/JAD-160527","article-title":"Stroke, vascular dementia, and Alzheimer's disease: molecular links","volume":"54","author":"Vijayan","year":"2016","journal-title":"J. Alzheimer's Dis.: JAD"},{"key":"2024041813305235900_B86","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2022.03.014","article-title":"The multifaceted impact of complement on atherosclerosis","volume":"351","author":"Kiss","year":"2022","journal-title":"Atherosclerosis"},{"key":"2024041813305235900_B87","first-page":"410","article-title":"The pathogenesis of hyaline arteriolosclerosis","volume":"122","author":"Gamble","year":"1986","journal-title":"Am. J. Pathol."},{"key":"2024041813305235900_B88","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030782","article-title":"Alzheimer's disease related single nucleotide polymorphisms and correlation with intracerebral hemorrhage incidence","volume":"101","author":"Sawyer","year":"2022","journal-title":"Medicine (Baltimore)."},{"key":"2024041813305235900_B89","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1161\/STROKEAHA.121.034372","article-title":"Role of complement component 3 in early erythrolysis in the hematoma after experimental intracerebral hemorrhage","volume":"52","author":"Wang","year":"2021","journal-title":"Stroke"},{"key":"2024041813305235900_B90","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1161\/STROKEAHA.119.025170","article-title":"Complement inhibition attenuates early erythrolysis in the hematoma and brain injury in aged rats","volume":"50","author":"Wang","year":"2019","journal-title":"Stroke"},{"key":"2024041813305235900_B91","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000486091","article-title":"Complement activation in capillary cerebral amyloid angiopathy","volume":"44","author":"Matsuo","year":"2017","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"2024041813305235900_B92","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00062-022-01231-5","article-title":"Cerebral superficial siderosis","volume":"33","author":"Weidauer","year":"2022","journal-title":"Clin. Neuroradiol."},{"key":"2024041813305235900_B93","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bpa.12218","article-title":"White matter changes in dementia: role of impaired drainage of interstitial fluid","volume":"25","author":"Weller","year":"2015","journal-title":"Brain Pathol."},{"key":"2024041813305235900_B94","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-01042-0","article-title":"Cerebral amyloid angiopathy aggravates perivascular clearance impairment in an Alzheimer's disease mouse model","volume":"8","author":"Kim","year":"2020","journal-title":"Acta Neuropathologica Commun."},{"key":"2024041813305235900_B95","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3233\/JAD-220494","article-title":"Complement 3 is a potential biomarker for cerebral amyloid angiopathy","volume":"89","author":"Saito","year":"2022","journal-title":"J. Alzheimer's Dis.:JAD"},{"key":"2024041813305235900_B96","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1365-2990.2005.00652.x","article-title":"Cerebral amyloid angiopathy in a 95+ cohort: complement activation and apolipoprotein E (ApoE) genotype","volume":"31","author":"Tanskanen","year":"2005","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"2024041813305235900_B97","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.mvr.2007.10.004","article-title":"Human postmortem brain-derived cerebrovascular smooth muscle cells express all genes of the classical complement pathway: a potential mechanism for vascular damage in cerebral amyloid angiopathy and Alzheimer's disease","volume":"75","author":"Walker","year":"2008","journal-title":"Microvasc. Res."},{"key":"2024041813305235900_B98","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-018-0540-2","article-title":"Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer's disease","volume":"6","author":"Hondius","year":"2018","journal-title":"Acta Neuropathologica Commun."},{"key":"2024041813305235900_B99","first-page":"1","article-title":"Maze rN, et al. Quantitative proteomic profiling of white matter in cases of cerebral amyloid angiopathy reveals upregulation of extracellular matrix proteins and clusterin","volume":"1","author":"Manousopoulou","year":"2020","journal-title":"Free Neuropathol."},{"key":"2024041813305235900_B100","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.1073\/pnas.1701137114","article-title":"Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways","volume":"114","author":"Wojtas","year":"2017","journal-title":"PNAS"},{"key":"2024041813305235900_B101","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1038\/s41598-020-60319-5","article-title":"Development of the clinical candidate PBD-C06, a humanized pGlu3-A\u03b2-specific antibody against Alzheimer's disease with reduced complement activation","volume":"10","author":"Hettmann","year":"2020","journal-title":"Sci. Rep."},{"key":"2024041813305235900_B102","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140966","article-title":"Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging","volume":"131","author":"Propson","year":"2021","journal-title":"J. Clin. Invest."},{"key":"2024041813305235900_B103","doi-asserted-by":"publisher","DOI":"10.7150\/thno.35841","article-title":"Microglia exacerbate white matter injury via complement C3\/C3aR pathway after hypoperfusion","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"2024041813305235900_B104","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/nan.12535","article-title":"Review: Clinical, genetic and neuroimaging features of frontotemporal dementia","volume":"45","author":"Convery","year":"2019","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"2024041813305235900_B105","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/brain\/awaa457","article-title":"Glial cells and adaptive immunity in frontotemporal dementia with tau pathology","volume":"144","author":"Hartnell","year":"2023","journal-title":"Brain"},{"key":"2024041813305235900_B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108398","article-title":"Tau pathology drives dementia risk-associated gene networks toward chronic inflammatory states and immunosuppression","volume":"33","author":"Rexach","year":"2020","journal-title":"Cell Rep."},{"key":"2024041813305235900_B107","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41582-019-0231-z","article-title":"Neuroinflammation in frontotemporal dementia","volume":"15","author":"Bright","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"2024041813305235900_B108","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0304-3940(01)01842-0","article-title":"Complement activation by neurofibrillary tangles in Alzheimer's disease","volume":"305","author":"Shen","year":"2001","journal-title":"Neurosci. Lett."},{"key":"2024041813305235900_B109","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/00005072-199605000-00010","article-title":"Role of complement in the aetiology of Pick's disease?","volume":"55","author":"Singhrao","year":"1996","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2024041813305235900_B110","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1017\/s0317167100029863","article-title":"Immune System Response in Alzheimer's Disease","volume":"16","author":"McGeer","year":"1998","journal-title":"Can. J. Neurol. Sci."},{"key":"2024041813305235900_B111","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/0006-8993(95)01257-5","article-title":"Neurofibrillary tangles of Guam parkinson-dementia are associated with reactive microglia and complement proteins","volume":"707","author":"Schwab","year":"1996","journal-title":"Brain Res."},{"key":"2024041813305235900_B112","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12974-022-02573-0","article-title":"Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study","volume":"19","author":"van der Ende","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"2024041813305235900_B113","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.celrep.2019.07.060","article-title":"Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy","volume":"28","author":"Wu","year":"2019","journal-title":"Cell Reports"},{"key":"2024041813305235900_B114","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/1742-2094-9-220","article-title":"Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice","volume":"9","author":"Britschgi","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"2024041813305235900_B115","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.4103\/1673-5374.332160","article-title":"Crry silencing alleviates Alzheimer's disease injury by regulating neuroinflammatory cytokines and the complement system","volume":"17","author":"Zhu","year":"2022","journal-title":"Neural Regeneration Res."},{"key":"2024041813305235900_B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2023.110685","article-title":"Complement C3a receptor antagonist alleviates tau pathology and ameliorates cognitive deficits in P301S mice","volume":"200","author":"Yao","year":"2023","journal-title":"Brain Res. Bull."},{"key":"2024041813305235900_B117","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.4049\/jimmunol.0901005","article-title":"Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease","volume":"183","author":"Fonseca","year":"2009","journal-title":"J. Immunol.(Baltimore, Md: 1950)"},{"issue":"5","key":"2024041813305235900_B118","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0306-8","article-title":"Dementia with Lewy bodies: an update and outlook","volume":"14","author":"Outeiro","year":"2019","journal-title":"Mol. Neurodegeneration"},{"key":"2024041813305235900_B119","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"2024041813305235900_B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105313","article-title":"Complement system changes in blood in Parkinson's disease and progressive Supranuclear Palsy\/Corticobasal Syndrome","volume":"108","author":"Khosousi","year":"2023","journal-title":"Parkinsonism Related Disorders"},{"key":"2024041813305235900_B121","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00702-018-1857-5","article-title":"Interleukin 6 and complement serum level study in Parkinson's disease","volume":"125","author":"Vesel\u00fd","year":"2018","journal-title":"J. Neural. Transmission (Vienna, Austria: 1996)"},{"key":"2024041813305235900_B122","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1021\/acschemneuro.2c00019","article-title":"Fibrinogen and Complement Factor H Are Promising CSF Protein Biomarkers for Parkinson's Disease with Cognitive Impairment\u2500A Proteomics-ELISA-Based Study","volume":"13","author":"Naskar","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"2024041813305235900_B123","doi-asserted-by":"publisher","first-page":"fcac343","DOI":"10.1093\/braincomms\/fcac343","article-title":"Identification of a possible proteomic biomarker in Parkinson's disease: discovery and replication in blood, brain and cerebrospinal fluid","volume":"5","author":"Winchester","year":"2022","journal-title":"Brain Commun."},{"key":"2024041813305235900_B124","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0022-510X(00)00498-6","article-title":"Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies","volume":"184","author":"Togo","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"2024041813305235900_B125","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/NEN.0b013e31820805b9","article-title":"Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease","volume":"70","author":"Depboylu","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2024041813305235900_B126","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-3-29","article-title":"Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study","volume":"3","author":"Loeffler","year":"2006","journal-title":"J. Neuroinflammation"},{"key":"2024041813305235900_B127","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/BF00427222","article-title":"Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins","volume":"84","author":"Yamada","year":"1992","journal-title":"Acta Neuropathol. (Berl)"},{"key":"2024041813305235900_B128","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0304-3940(00)01090-9","article-title":"Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein-immunohistochemistry","volume":"286","author":"Iseki","year":"2000","journal-title":"Neurosci. Lett."},{"key":"2024041813305235900_B129","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-016-0164-y","article-title":"Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease","volume":"9","author":"Dumitriu","year":"2016","journal-title":"BMC Med. Genet."},{"key":"2024041813305235900_B130","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.4049\/jimmunol.1900494","article-title":"Size-Selective Phagocytic Clearance of Fibrillar \u03b1-Synuclein through Conformational Activation of Complement Receptor 4","volume":"204","author":"Juul-Madsen","year":"2020","journal-title":"J. Immunol."},{"key":"2024041813305235900_B131","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.bbrc.2007.04.055","article-title":"Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112","volume":"357","author":"Klegeris","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2024041813305235900_B132","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02225-9","article-title":"Alpha-synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity","volume":"18","author":"Gregersen","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"2024041813305235900_B133","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.4049\/jimmunol.1900494","article-title":"Size-selective phagocytic clearance of fibrillar \u03b1-synuclein through conformational activation of complement receptor 4","volume":"204","author":"Juul-Madsen","year":"2020","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"key":"2024041813305235900_B134","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2147\/JIR.S299927","article-title":"Microglial activation mediates noradrenergic locus coeruleus neurodegeneration via complement receptor 3 in a rotenone-induced Parkinson's disease mouse model","volume":"14","author":"Jing","year":"2021","journal-title":"J. Inflammation Res."},{"key":"2024041813305235900_B135","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.brainres.2007.08.033","article-title":"Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity","volume":"1178","author":"Liang","year":"2007","journal-title":"Brain Res."},{"key":"2024041813305235900_B136","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jneuroim.2011.05.006","article-title":"Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease","volume":"236","author":"Depboylu","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"2024041813305235900_B137","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2024041813305235900_B138","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00702-010-0430-7","article-title":"Neuroinflammation in Huntington's disease","volume":"117","author":"Moller","year":"2010","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"2024041813305235900_B139","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1006\/exnr.1999.7170","article-title":"Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease","volume":"159","author":"Singhrao","year":"1999","journal-title":"Exp. Neurol."},{"key":"2024041813305235900_B140","first-page":"31","article-title":"Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system","volume":"150","author":"Gasque","year":"1997","journal-title":"Am. J. Pathol."},{"key":"2024041813305235900_B141","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1021\/pr0700753","article-title":"Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates","volume":"6","author":"Dalrymple","year":"2007","journal-title":"J. Proteome Res."},{"key":"2024041813305235900_B142","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3233\/JHD-130049","article-title":"A critical evaluation of inflammatory markers in Huntington's Disease plasma","volume":"2","author":"Silajdzic","year":"2013","journal-title":"J. Huntingtons Dis."},{"key":"2024041813305235900_B143","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/braincomms\/fcac309","article-title":"Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity","volume":"4","author":"Caron","year":"2022","journal-title":"Brain Commun."},{"key":"2024041813305235900_B144","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"2024041813305235900_B145","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3233\/JHD-2012-120021","article-title":"Genetic deficiency of complement component 3 does not alter disease progression in a mouse model of Huntington's disease","volume":"1","author":"Larkin","year":"2012","journal-title":"J. Huntingtons Dis."},{"key":"2024041813305235900_B146","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1096\/fj.05-5814com","article-title":"Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration","volume":"20","author":"Woodruff","year":"2006","journal-title":"FASEB J."},{"key":"2024041813305235900_B147","article-title":"Annexon: Pipeline - Annexon Biosciences","year":"2023"},{"key":"2024041813305235900_B148","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2990.1989.tb01231.x","article-title":"Immunocytochemical localization of the terminal complement complex in multiple sclerosis","volume":"15","author":"Compston","year":"1989","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"2024041813305235900_B149","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/ana.1123","article-title":"Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions","volume":"50","author":"Peterson","year":"2001","journal-title":"Ann. Neurol."},{"key":"2024041813305235900_B150","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jneuroim.2010.03.014","article-title":"Elevated plasma C4a levels in multiple sclerosis correlate with disease activity","volume":"223","author":"Ingram","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"2024041813305235900_B151","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","article-title":"Inflammatory cortical demyelination in early multiple sclerosis","volume":"365","author":"Lucchinetti","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2024041813305235900_B152","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-11","article-title":"Meningeal and cortical grey matter pathology in multiple sclerosis","volume":"12","author":"Popescu","year":"2012","journal-title":"BMC Neurol."},{"key":"2024041813305235900_B153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2051-5960-2-53","article-title":"Complement activation in multiple sclerosis plaques: an immunohistochemical analysis","volume":"2","author":"Ingram","year":"2014","journal-title":"Acta Neuropathologica Commun."},{"key":"2024041813305235900_B154","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/ana.24398","article-title":"Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus","volume":"77","author":"Michailidou","year":"2015","journal-title":"Ann. Neurol."},{"key":"2024041813305235900_B155","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/ana.25365","article-title":"Meningeal inflammation and cortical demyelination in acute multiple sclerosis","volume":"84","author":"Bevan","year":"2018","journal-title":"Ann. Neurol."},{"key":"2024041813305235900_B156","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13054","article-title":"The association between neurodegeneration and local complement activation in the thalamus to progressive multiple sclerosis outcome","volume":"32","author":"Cooze","year":"2022","journal-title":"Brain Pathol."},{"key":"2024041813305235900_B157","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12974-016-0611-x","article-title":"Complement is activated in progressive multiple sclerosis cortical grey matter lesions","volume":"13","author":"Watkins","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"2024041813305235900_B158","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/bpa.12546","article-title":"Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis","volume":"28","author":"Loveless","year":"2018","journal-title":"Brain Pathol."},{"key":"2024041813305235900_B159","doi-asserted-by":"publisher","first-page":"1094106","DOI":"10.3389\/fncel.2023.1094106","article-title":"Complement activation and increased anaphylatoxin receptor expression are associated with cortical grey matter lesions and the compartmentalised inflammatory response of multiple sclerosis","volume":"17","author":"Evans","year":"2023","journal-title":"Front. Cell. Neurosci."},{"key":"2024041813305235900_B160","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1177\/1352458512438238","article-title":"Systemic complement profiling in multiple sclerosis as a biomarker of disease state","volume":"18","author":"Ingram","year":"2012","journal-title":"Mult. Scler."},{"key":"2024041813305235900_B161","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/brain\/awq085","article-title":"Complement regulator factor H as a serum biomarker of multiple sclerosis disease state","volume":"133","author":"Ingram","year":"2010","journal-title":"Brain: J. Neurol."},{"key":"2024041813305235900_B162","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1365-2249.2008.03830.x","article-title":"Complement in multiple sclerosis: its role in disease and potential as a biomarker","volume":"155","author":"Ingram","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"2024041813305235900_B163","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/1352458516669002","article-title":"Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"23","author":"Hakobyan","year":"2017","journal-title":"Mult. Scler."},{"key":"2024041813305235900_B164","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s12026-017-8961-8","article-title":"The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis","volume":"65","author":"Tatomir","year":"2017","journal-title":"Immunol. Res."},{"key":"2024041813305235900_B165","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.4049\/jimmunol.136.12.4456","article-title":"Activated terminal complement in cerebrospinal fluid in Guillain-Barr\u00e9 syndrome and multiple sclerosis","volume":"136","author":"Sanders","year":"1986","journal-title":"J. Immunol.(Baltimore, Md: 1950)"},{"key":"2024041813305235900_B166","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2000.101002116.x","article-title":"Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system","volume":"101","author":"Jongen","year":"2000","journal-title":"Acta Neurol. Scand."},{"key":"2024041813305235900_B167","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1155\/2005\/806573","article-title":"Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease","volume":"21","author":"Finehout","year":"2005","journal-title":"Dis. Markers"},{"key":"2024041813305235900_B168","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122048","article-title":"Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis","volume":"10","author":"Aeinehband","year":"2015","journal-title":"PloS ONE"},{"key":"2024041813305235900_B169","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clim.2016.04.003","article-title":"Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function","volume":"166-167","author":"Lindblom","year":"2016","journal-title":"Clin. Immunol."},{"key":"2024041813305235900_B170","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/acn3.50893","article-title":"Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis","volume":"6","author":"Magliozzi","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"2024041813305235900_B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577147","article-title":"Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis","volume":"340","author":"H\u00e5kansson","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"2024041813305235900_B172","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6%3c707::AID-ANA3%3e3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann. Neurol."},{"key":"2024041813305235900_B173","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1191\/1352458502ms785rr","article-title":"The pathology of primary progressive multiple sclerosis","volume":"8","author":"Br\u00fcck","year":"2002","journal-title":"Mult. Scler."},{"key":"2024041813305235900_B174","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol. (Berl)"},{"key":"2024041813305235900_B175","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.600656","article-title":"An \u201cOutside-In\u201d and \u201cInside-Out\u201d Consideration of Complement in the Multiple Sclerosis Brain: Lessons From Development and Neurodegenerative Diseases","volume":"14","author":"Morgan","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"2024041813305235900_B176","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.4049\/jimmunol.152.11.5477","article-title":"Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis","volume":"152","author":"Piddlesden","year":"1994","journal-title":"J. Immunol.(Baltimore, Md: 1950)"},{"key":"2024041813305235900_B177","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.immuni.2019.12.004","article-title":"Targeted Complement Inhibition at Synapses Prevents Microglial Synaptic Engulfment and Synapse Loss in Demyelinating Disease","volume":"52","author":"Werneburg","year":"2020","journal-title":"Immunity"},{"key":"2024041813305235900_B178","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bbi.2020.03.004","article-title":"Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis","volume":"87","author":"Hammond","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"2024041813305235900_B179","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4049\/jimmunol.168.1.458","article-title":"The membrane attack complex of complement causes severe demyelination associated with acute axonal injury","volume":"168","author":"Mead","year":"2002","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"key":"2024041813305235900_B180","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/labinvest.3700015","article-title":"Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis","volume":"84","author":"Mead","year":"2004","journal-title":"Lab. Invest."},{"key":"2024041813305235900_B181","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med."},{"key":"2024041813305235900_B182","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1192\/bjp.171.6.502","article-title":"Excess mortality of schizophrenia. A meta-analysis","volume":"171","author":"Brown","year":"1997","journal-title":"Br. J. Psychiatry: J. Mental Sci."},{"key":"2024041813305235900_B183","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1192\/bjp.177.3.212","article-title":"Causes of the excess mortality of schizophrenia","volume":"177","author":"Brown","year":"2000","journal-title":"Br. J. Psychiatry: J. Mental Sci."},{"issue":"5","key":"2024041813305235900_B184","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1073\/pnas.052023499","article-title":"Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia","volume":"99","author":"Cannon","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2024041813305235900_B185","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.biopsych.2014.05.023","article-title":"Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk","volume":"77","author":"Cannon","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"2024041813305235900_B186","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/jnnp.65.4.446","article-title":"Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia","volume":"65","author":"Garey","year":"1998","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"2024041813305235900_B187","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archpsyc.57.1.65","article-title":"Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia","volume":"57","author":"Glantz","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"2024041813305235900_B188","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0022-3956(82)90038-3","article-title":"Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?","volume":"17","author":"Feinberg","year":"1982","journal-title":"J. Psychiatr. Res."},{"key":"2024041813305235900_B189","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0006-8993(79)90349-4","article-title":"Synaptic density in human frontal cortex - developmental changes and effects of aging","volume":"163","author":"Huttenlocher","year":"1979","journal-title":"Brain Res."},{"key":"2024041813305235900_B190","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1126\/science.274.5290.1133","article-title":"Synaptic activity and the construction of cortical circuits","volume":"274","author":"Katz","year":"1996","journal-title":"Science (New York, NY)"},{"key":"2024041813305235900_B191","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-8628(200021)97:1%3c12::AID-AJMG3%3e3.0.CO;2-U","article-title":"Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics","volume":"97","author":"Cardno","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"2024041813305235900_B192","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/archpsyc.60.12.1187","article-title":"Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies","volume":"60","author":"Sullivan","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"2024041813305235900_B193","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nature08185","article-title":"Common polygenic variation contributes to risk of schizophrenia and bipolar disorder","volume":"460","author":"Purcell","year":"2009","journal-title":"Nature"},{"key":"2024041813305235900_B194","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nature08186","article-title":"Common variants conferring risk of schizophrenia","volume":"460","author":"Stefansson","year":"2009","journal-title":"Nature"},{"key":"2024041813305235900_B195","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nature08192","article-title":"Common variants on chromosome 6p22.1 are associated with schizophrenia","volume":"460","author":"Shi","year":"2009","journal-title":"Nature"},{"key":"2024041813305235900_B196","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.4049\/jimmunol.132.6.3019","article-title":"The molecular basis for the difference in immune hemolysis activity of the Chido and Rodgers isotypes of human complement component C4","volume":"132","author":"Isenman","year":"1984","journal-title":"J. Immunol."},{"key":"2024041813305235900_B197","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1002\/j.1460-2075.1984.tb02052.x","article-title":"A comparison of the properties of two classes, C4A and C4B, of the human complement component C4","volume":"3","author":"Law","year":"1984","journal-title":"EMBO J."},{"key":"2024041813305235900_B198","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Consortium","year":"2014","journal-title":"Nature"},{"key":"2024041813305235900_B199","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/ng.940","article-title":"Genome-wide association study identifies five new schizophrenia loci","volume":"43","author":"Study","year":"2011","journal-title":"Nat. Genet."},{"key":"2024041813305235900_B200","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","article-title":"Mapping genomic loci implicates genes and synaptic biology in schizophrenia","volume":"604","author":"Trubetskoy","year":"2022","journal-title":"Nature"},{"key":"2024041813305235900_B201","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1096\/fj.13-230706","article-title":"The novel complement inhibitor human CUB and Sushi multiple domains 1 (CSMD1) protein promotes factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly","volume":"27","author":"Escudero-Esparza","year":"2013","journal-title":"FASEB J.: Off. Publ. Federation Am. Societies Exp. Biol."},{"key":"2024041813305235900_B202","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.4049\/jimmunol.176.7.4419","article-title":"CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues","volume":"176","author":"Kraus","year":"2006","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"key":"2024041813305235900_B203","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-12522-w","article-title":"Rare mutations in the complement regulatory gene CSMD1 are associated with male and female infertility","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"2024041813305235900_B204","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.11.291427","article-title":"CUB and Sushi Multiple Domains 1 (CSMD1) opposes the complement cascade in neural tissues","author":"Baum","year":"2020","journal-title":"bioRxiv"},{"key":"2024041813305235900_B205","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2089-4","article-title":"Altered expression of the CSMD1 gene in the peripheral blood of schizophrenia patients","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Psychiatry"},{"key":"2024041813305235900_B206","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.1c03637","article-title":"mRNA expression of the CUB and sushi multiple domains 1 (CSMD1) and its serum protein level as predictors for psychosis in the familial high-risk children and young adults","volume":"6","author":"Abd El Gayed","year":"2021","journal-title":"ACS Omega"},{"key":"2024041813305235900_B207","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00406-022-01409-5","article-title":"Deregulation of complement components C4A and CSMD1 peripheral expression in first-episode psychosis and links to cognitive ability","volume":"272","author":"Hatzimanolis","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"2024041813305235900_B208","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000177","article-title":"Whole-exome sequencing associates novel CSMD1 gene mutations with familial Parkinson disease","volume":"3","author":"Ruiz-Mart\u00ednez","year":"2017","journal-title":"Neurol. Genet."},{"key":"2024041813305235900_B209","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2350-15-2","article-title":"Genome-wide association study of bipolar disorder in Canadian and UK populations corroborates disease loci including SYNE1 and CSMD1","volume":"15","author":"Xu","year":"2014","journal-title":"BMC Med. Genet."},{"key":"2024041813305235900_B210","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/hmg\/ddn388","article-title":"Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis","volume":"18","author":"Baranzini","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"2024041813305235900_B211","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/gene.2010.52","article-title":"Replication of top markers of a genome-wide association study in multiple sclerosis in Spain","volume":"12","author":"Cavanillas","year":"2010","journal-title":"Genes Immunity"},{"key":"2024041813305235900_B212","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2040-2392-5-1","article-title":"Exome sequencing of extended families with autism reveals genes shared across neurodevelopmental and neuropsychiatric disorders","volume":"5","author":"Cukier","year":"2014","journal-title":"Mol. Autism"},{"key":"2024041813305235900_B213","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/ejhg.2008.133","article-title":"Transmitted duplication of 8p23.1\u20138p23.2 associated with speech delay, autism and learning difficulties","volume":"17","author":"Glancy","year":"2008","journal-title":"Eur. J. Hum. Genet."},{"key":"2024041813305235900_B214","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41593-020-00763-8","article-title":"Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice","volume":"24","author":"Yilmaz","year":"2021","journal-title":"Nat. Neurosci."},{"key":"2024041813305235900_B215","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000604","article-title":"Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction","volume":"18","author":"Comer","year":"2020","journal-title":"PLoS Biol."},{"key":"2024041813305235900_B216","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41380-019-0479-0","article-title":"The complement system in schizophrenia: where are we now and what's next?","volume":"25","author":"Woo","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"2024041813305235900_B217","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.schres.2017.12.012","article-title":"Complement system biomarkers in first episode psychosis","volume":"204","author":"Kopczynska","year":"2019","journal-title":"Schizophr. Res."},{"key":"2024041813305235900_B218","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000492331","article-title":"X-Aptamer Technology Identifies C4A and ApoB in Blood as Potential Markers for Schizophrenia","volume":"5","author":"Walss-Bass","year":"2019","journal-title":"Mol. Neuropsychiatry"},{"key":"2024041813305235900_B219","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1080\/14712598.2021.1884223","article-title":"Targeting the complement system in neuromyelitis optica spectrum disorder","volume":"21","author":"Asavapanumas","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"2024041813305235900_B220","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: A review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"2024041813305235900_B221","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.tips.2022.02.006","article-title":"Targeting complement in neurodegeneration: challenges, risks, and strategies","volume":"43","author":"Zelek","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"2024041813305235900_B222","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/ana.24406","article-title":"Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology","volume":"78","author":"Drouin-Ouellet","year":"2015","journal-title":"Ann. Neurol."},{"key":"2024041813305235900_B223","doi-asserted-by":"publisher","DOI":"10.1038\/srep41316","article-title":"Impairment of blood-brain barrier is an early event in R6\/2 mouse model of Huntington Disease","volume":"7","author":"Di Pardo","year":"2017","journal-title":"Sci. Rep."},{"key":"2024041813305235900_B224","article-title":"Alexion: Pipeline | Alexion","year":"2023"},{"key":"2024041813305235900_B225","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061117","article-title":"Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives","volume":"14","author":"Pardo-Moreno","year":"2022","journal-title":"Pharmaceutics"},{"key":"2024041813305235900_B226","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106549","article-title":"Current druggable targets for therapeutic control of Alzheimer's disease","volume":"109","author":"Gupta","year":"2021","journal-title":"Contemporary Clin. Trials"},{"key":"2024041813305235900_B227","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/13543784.2021.2017881","article-title":"What have we learned from past failures of investigational drugs for Alzheimer's disease?","volume":"30","author":"Imbimbo","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2024041813305235900_B228","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2024041813305235900_B229","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10091527","article-title":"Immunotherapies for Alzheimer's Disease-A Review","volume":"10","author":"Valiukas","year":"2022","journal-title":"Vaccines"},{"key":"2024041813305235900_B230","doi-asserted-by":"publisher","DOI":"10.52965\/001c.31925","article-title":"Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review","volume":"10","author":"Haddad","year":"2022","journal-title":"Health Psychol. Res."},{"key":"2024041813305235900_B231","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"ENGAGE and EMERGE: Truth and consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimer's & Dementia: J. Alzheimer's Assoc."},{"key":"2024041813305235900_B232","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility","volume":"325","author":"Alexander","year":"2021","journal-title":"JAMA"},{"key":"2024041813305235900_B233","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimer's & Dementia (New York, N. Y.)"},{"key":"2024041813305235900_B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100982","article-title":"Lecanemab reduces brain amyloid-\u03b2 and delays cognitive worsening","volume":"4","author":"Knopman","year":"2023","journal-title":"Cell Reports Med."},{"key":"2024041813305235900_B235","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nm0197-77","article-title":"Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis","volume":"3","author":"Velazquez","year":"1997","journal-title":"Nat. Med."},{"key":"2024041813305235900_B236","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1096\/fj.11-202382","article-title":"Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis","volume":"26","author":"Pavlovski","year":"2012","journal-title":"FASEB J.: Off. Publ. Federation Am. Societies Exp. Biol."},{"key":"2024041813305235900_B237","doi-asserted-by":"publisher","DOI":"10.1177\/1759091416687871","article-title":"C5a increases the injury to primary neurons elicited by fibrillar amyloid beta","volume":"9","author":"Hernandez","year":"2017","journal-title":"ASN Neuro"},{"key":"2024041813305235900_B238","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225417","article-title":"C5aR agonist enhances phagocytosis of fibrillar and non-fibrillar A\u03b2 amyloid and preserves memory in a mouse model of familial Alzheimer's disease","volume":"14","author":"Panayiotou","year":"2019","journal-title":"PLoS ONE"},{"key":"2024041813305235900_B239","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neulet.2012.10.012","article-title":"Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE","volume":"531","author":"Hu","year":"2012","journal-title":"Neurosci. Lett."},{"key":"2024041813305235900_B240","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13041-022-00937-4","article-title":"Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders","volume":"15","author":"Alajangi","year":"2022","journal-title":"Mol. Brain"},{"key":"2024041813305235900_B241","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1212\/WNL.0b013e3181a41228","article-title":"Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS","volume":"72","author":"Henkel","year":"2009","journal-title":"Neurology"},{"key":"2024041813305235900_B242","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron"},{"key":"2024041813305235900_B243","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/jpm12071071","article-title":"Taking Advantages of Blood-Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?","volume":"12","author":"Alarcan","year":"2022","journal-title":"J. Personalized Med."},{"key":"2024041813305235900_B244","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203217","article-title":"A Phase 2 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX005 in Patients with, or at Risk of, Manifest Huntington's Disease (HD) (S32.009)","author":"Kumar","year":"2023","journal-title":"Neurology"},{"key":"2024041813305235900_B245","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145649","article-title":"C1q and central nervous system disorders","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"2024041813305235900_B246","article-title":"Biosciences A: Game-changing medicines for complement mediated diseases","year":"2023"},{"key":"2024041813305235900_B247","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/s41593-022-01131-4","article-title":"A CRISPRi\/a platform in human iPSC-derived microglia uncovers regulators of disease states","volume":"25","author":"Dr\u00e4ger","year":"2022","journal-title":"Nat. Neurosci."},{"key":"2024041813305235900_B248","doi-asserted-by":"publisher","first-page":"25068","DOI":"10.1016\/S0021-9258(19)74572-4","article-title":"Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells","volume":"268","author":"Gasque","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2024041813305235900_B249","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/intimm\/dxg008","article-title":"Expression of H-ficolin\/Hakata antigen, mannose-binding lectin-associated serine protease (MASP)-1 and MASP-3 by human glioma cell line T98G","volume":"15","author":"Kuraya","year":"2003","journal-title":"Int. Immunol."},{"key":"2024041813305235900_B250","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0304-3940(93)90652-2","article-title":"Complement gene expression in neuroblastoma and astrocytoma cell lines of human origin","volume":"157","author":"Walker","year":"1993","journal-title":"Neurosci. Lett."},{"key":"2024041813305235900_B251","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1006\/exnr.1999.7199","article-title":"Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor","volume":"160","author":"Veerhuis","year":"1999","journal-title":"Exp. Neurol."},{"key":"2024041813305235900_B252","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.4049\/jimmunol.149.4.1381","article-title":"Expression of complement components of the alternative pathway by glioma cell lines","volume":"149","author":"Gasque","year":"1992","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"key":"2024041813305235900_B253","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0165-5728(92)90020-L","article-title":"Interferon-gamma regulation of C3 gene expression in human astroglioma cells","volume":"38","author":"Barnum","year":"1992","journal-title":"J. Neuroimmunol."},{"key":"2024041813305235900_B254","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0169-328X(92)90017-6","article-title":"Complement gene expression in human brain: comparison between normal and Alzheimer disease cases","volume":"14","author":"Walker","year":"1992","journal-title":"Brain Res. Mol. Brain Res."},{"key":"2024041813305235900_B255","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0006-8993(98)00811-7","article-title":"Expression of complement C4 and C9 genes by human astrocytes","volume":"809","author":"Walker","year":"1998","journal-title":"Brain Res."},{"key":"2024041813305235900_B256","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s004010050896","article-title":"Complement C1-inhibitor expression in Alzheimer's disease","volume":"96","author":"Veerhuis","year":"1998","journal-title":"Acta Neuropathol. (Berl)"},{"key":"2024041813305235900_B257","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0006-8993(95)00041-N","article-title":"Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease","volume":"675","author":"Walker","year":"1995","journal-title":"Brain Res."},{"key":"2024041813305235900_B258","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/(SICI)1098-1136(199905)26:3%3c201::AID-GLIA2%3e3.0.CO;2-M","article-title":"Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells","volume":"26","author":"Davoust","year":"1999","journal-title":"Glia"},{"key":"2024041813305235900_B259","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.4049\/jimmunol.160.7.3543","article-title":"The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis","volume":"160","author":"Gasque","year":"1998","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"key":"2024041813305235900_B260","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0165-5728(96)00015-X","article-title":"Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins","volume":"66","author":"Gasque","year":"1996","journal-title":"J. Neuroimmunol."},{"key":"2024041813305235900_B261","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0165-5728(93)90022-q","article-title":"Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes","volume":"47","author":"Yang","year":"1993","journal-title":"J. Neuroimmunol."},{"key":"2024041813305235900_B262","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0165-5728(92)90051-L","article-title":"Human astrocytes express membrane cofactor protein (CD46), a regulator of complement activation","volume":"36","author":"Gordon","year":"1992","journal-title":"J. Neuroimmunol."},{"key":"2024041813305235900_B263","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/icb.1993.24","article-title":"Detection of mosaic protein mRNA in human astrocytes","volume":"71","author":"Avery","year":"1993","journal-title":"Immunol. Cell Biol."}],"updated-by":[{"DOI":"10.1042\/cs-2023-0513c_cor","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000}}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/138\/6\/387\/956017\/cs-2023-0513c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/138\/6\/387\/956017\/cs-2023-0513c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T09:31:17Z","timestamp":1713432677000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/138\/6\/387\/234215\/The-complement-system-in-neurodegenerative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":263,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3,20]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20230513","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,3]]}}}